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INTRODUCTION
Mortality from Acute Myocardial Infarction (AMI) is said to be declining. The decline 
in mortality has been ascribed to a combination of community-wide preventive strategies and 
improved treatment. 
The  advent  of  mobile  CCU,  increased  use  of  thrombolysis  (including  pre-hospital 
thrombolysis),  Intensive  Coronary  Care  and  early  interventional  procedures  have  all  been 
highlighted for the ‘decline’ in morbidity and mortality.(1)
Recent  large  scale  randomized  controlled  thrombolytic  trials  have  reported  30  day 
mortalities of 6–10% with mortality as low as 2.5% in trials of primary angioplasty (2).
But in actual clinical practice, many patients do not receive optimal treatment, including 
thrombolysis. Series from North America and Europe suggest that thrombolysis rates are in the 
region of 25%. (8, 9)
In addition, many patients are not managed in coronary care units and many are elderly. 
Thus the hospital  mortality of unselected patients with acute myocardial  infarction may be 
considerably higher  than suggested by  the  results  of  large  scale  trials  of  thrombolysis  and 
primary angioplasty.
           Hence AMI still remains as one of the main causes of morbidity and mortality.
A number of multivariable prognostic models have been developed in populations of 
patients with ST-segment elevation acute myocardial infarction. Considerable variability exists 
in  the  risk for  adverse  events  across  the  spectrum of  ACS especially,  in  ST elevation MI 
(STEMI). 
Different  presenting  characteristics,  in  large  part  related  to  identification  of  varying 
levels of risk, have become important factors in deciding on the level of care and choice of 
interventional and medical therapies.
     This scenario necessitates an in depth analysis of predictors of in hospital mortality in 
AMI.
AIM OF THE STUDY
It  is  an  enigma  why  some  patients  with  AMI succumb to  the  disease  while  others 
survive despite almost similar features and management protocols.
Most models of predictors of mortality have been derived from databases from clinical 
trials, which tend to exclude high-risk patients and are not fully representative of the broad 
spectrum of patients encountered in general clinical practice. 
Other predictive models have been developed, which may also be limited by selective 
bias of inclusion criteria.
Some of the most robust predictors of mortality have been developed in the selected 
population  of  patients  with  ST-segment  elevation  myocardial  infarction  treated  with 
fibrinolytic therapy, and these models may not be relevant to most patients seen in practice.
Thus earlier studies have elucidated many possible predictors.  However the value of 
such studies varies in its universal applicability.
Hence it is necessary to determine factors that are predictive of death across the entire 
spectrum of an unselected population of AMI patients.
In addition it  remains imperative that,  parameters that  predict mortality be evaluated 
based on clinical features as well as simple and easily available investigations. 
Hence  it  is  mandatory  to  analyze  such  clinical  parameters  that  are  more  uniformly 
acceptable and tenable as predictors of in-hospital mortality.
In  addition  presently  echocardiographic  evaluation  is  widely  used  in  acute  coronary 
events for diagnosis and management.
However, the utilization of echocardiography as a prognostic indicator remains as an 
area for study and analysis. 
Hence  it  is  an  important  purpose  of  this  study  is  to  identify  findings  on  early 
echocardiograms that are associated with mortality after AMI.
Further it  is  necessary to assess the interaction of such findings with treatment,  and 
hence determine whether any of these echocardiographic features could provide insights into 
the survival benefit.
With  routine  use  and  availability  of  Tissue  Doppler  Imaging  (TDI)  at  the  bedside, 
whether  analysis  of  prediction  of  mortality  in  AMI  using  TDI  parameters  would  be  an 
important variable in risk stratification.
Aim of this study is to evaluate the   clinical and echocardiographic predictors   of in-
hospital mortality in acute ST elevation myocardial infarction in unselected patients admitted in 
Coronary Care Unit. 
REVIEW OF LITERATURE
In a study of Hospital mortality of acute myocardial infarction in the thrombolytic 
era  N  G  Mahon  et.al..(4) Unselected  patients  from  a  centre  with  coronary  intervention 
facilities, the hospital mortality of acute myocardial infarction was 18%.(Table 1) This is a 
reflection of the design of the study which included all ages and all hospital cases of acute 
myocardial infarction, not simply those admitted to coronary care. 
Accordingly 30% of patients were over 75 years and mortality in this group was 30%, as 
opposed to 14% in those under 75(3, 5). Other studies reporting the hospital mortality of acute 
myocardial infarction since the introduction of thrombolysis have produced disparate results, 
with hospital mortalities ranging from 8.4% to 23%. 
This disparity is determined by differences in study populations, with studies limited to 
younger ages or coronary care cases showing lower mortality than studies of unselected cases. 
Distribution of risk factors
Smoking  history  (63%),  diabetes  mellitus  (28%),  family  history  (22%),  and 
hypertension (32%) did not differ significantly from the other centre series. The occurrence of 
left  ventricular  failure  (33%),  ventricular  arrhythmias  11%),  and  post  infarction  angina  or 
reinfarction (15%) lower than in the tertiary centre(45%,18% and 34% respectively).
PREDICTORS OF HOSPITAL MORTALITY
These are shown in Table 2. The mean age of patients dying was 73 years v 67 years in 
patients  surviving.(10,11)  Patients  age  was  a  predictor  of  mortality  in  hospital  in  both 
univariate  (p  <  0.001)  and  multivariate  analysis  (p  <  0.001).  Other  predictors  of  hospital 
mortality by univariate analysis included sex, the use of thrombolysis, and the occurrence of 
left ventricular failure, cardiogenic shock, ventricular arrhythmias, and heart block requiring 
temporary pacing. Other independent predictors of mortality following multivariate analysis 
were left ventricular failure, shock, ventricular arrhythmias, management outside the CCU, and 
the development of reinfarction.
Table 1. Summarizes clinical and demographic features, complication rates, and outcomes 
of patients admitted with acute myocardial infarction.
Table 2 .Predictors of   in hospital mortality
In  this  study,  Thrombolytic  treatment  was  associated  with  improved  outcome  in 
univariate but not multivariate analysis. (18)The major influences on the rate of thrombolysis 
are  the  presence of  ECG criteria  for  thrombolysis  and the  time of  presentation with  acute 
myocardial infarction. There was also evidence for underutilization of other drug treatments. 
The rate of aspirin use was 83%, which is comparable with data from other centers.
Cigarette  smoking  was  a  univariate  predictor  of  lower  hospital  mortality.  This 
phenomenon has been observed in several large thrombolytic trials  and may reflect younger 
age at presentation in smokers (mean age of smokers in this study was 65 years v 70 years in 
non-smokers),  a  lower  prevalence  of  other  risk  factors,  a  higher  proportion  of  arrhythmic 
deaths before reaching hospital,  reversal of risk following cessation of smoking during the 
hospital admission or a better response to thrombolysis owing to the predominantly thrombotic 
nature of the lesion.
A  family  history  of  premature  coronary  disease  was  also  associated  with  a  better 
outcome. Again this reflects the younger age of patients with a family history (mean age 62 
years v 70 years in the remaining population), and may be a result of earlier presentation in 
patients with a family history or of more difficulty in eliciting a family history from elderly 
patients.
The observation of a higher hospital mortality in the tertiary referral centre, where the 
coronary intervention rate was high, might be construed as evidence against the benefits of 
coronary interventions in acute myocardial infarction.(6,7)  
Reports from the  VANQWISH and OASIS trials,  and previously from trials such as 
TIMI II, have questioned the benefit of coronary interventions in acute coronary syndromes 
and acute myocardial infarction. (19-27).
However,  data  from  the  GUSTO  trial  suggest  higher  morbidity  among  patients 
undergoing  fewer  interventions  and  a  study  of  varying  practices  in  16  Kaiser  Permanente 
hospitals  showed  a  significant  inverse  correlation  between  higher  intervention  rates  and 
mortality. 
In the present study, the apparent paradox of a higher mortality in the centre with the 
higher intervention rates may be explained by a bias in demographics.(12,13)
The  non-tertiary  centre  patients  were  considerably  younger,  they  had  fewer  co 
morbidities,  and  more  of  these  patients  were  managed  in  coronary  care  and  received 
thrombolysis.
Cardiogenic Shock Complicating Acute Myocardial Infarction 
While  analyzing  the  SHOCK  (SHould we  emergently  revascularize  Occluded 
Coronaries in cardiogenic shock?) trial, Judith S. Hochman finds that though,the strategy of 
early revascularization is superior to initial aggressive medical therapy, despite the advantages 
of  early  percutanous  coronary  intervention  (PCI)  or  coronary  artery  bypass  graft  surgery 
(CABG), once shock is diagnosed, the mortality rate remains high ( 50%), and half  of the 
deaths occur within the first 48 hours. This may be caused by irreversible extensive myocardial 
or vital-organ damage. 
He further suggests,   that  a systemic inflammatory response, complement activation, 
release of inflammatory cytokines, expression of inducible nitric oxide (NO) synthase (iNOS), 
and inappropriate vasodilation may play an important role not only in the genesis of shock but 
also in outcome after shock. New insights and therapies are needed.
Classic Shock Paradigm
The  underlying  pathophysiology  of  CS  is  profound  depression of  myocardial 
contractility, resulting in a vicious spiral of reduced cardiac output (CO), low blood pressure, 
further coronary insufficiency, and further reduction in contractility and CO(28). The classic 
paradigm predicts  that  compensatory systemic vasoconstriction with high systemic vascular 
resistance (SVR) should occur in response to the depression of CO (Figure 1).
Autopsy studies have shown that the pathological basis of CS is extensive MI. Varying 
pathological  stages  of  infarction  confirm  the  stuttering  and  progressive  nature  of  the 
myocardial necrosis as a corollary of the vicious spiral.  Combined new and old infarctions 
consistently involve at least 40% of the LV myocardium in these autopsy specimens.(29)
Figure  1.  Classic  shock paradigm,  as  illustrated by  S.  Hollenberg,  is  shown in black.  The 
influence of the inflammatory response syndrome initiated by a large MI is illustrated in red. 
LVEDP indicates left ventricular end-diastolic pressure. 
Observations That Challenge the Classic Paradigm
There  are  several  observations  derived  from  the  SHOCK  (SHould we  emergently 
revascularize Occluded Coronaries in cardiogenic shock?) trial and registry about patients with 
CS due to  LV failure  not  easily  explainable  by our  traditional  concepts. These include the 
following: 
Average LV ejection fraction (EF) is only moderately severely depressed (30%), with a 
wide range of EFs and LV sizes noted. 
SVR on vasopressors  is  not  elevated  on  average,  with  a  very wide  range  of  SVRs 
measured. 
A  clinically  evident  systemic inflammatory  response  syndrome is  often  present  in 
patients with CS. 
Most survivors have class I congestive heart failure (CHF) status. 
Surprisingly,  an  average  EF  of  30%  was  observed  in  left  ventriculograms and 
echocardiograms obtained soon after shock diagnosis in patients with confirmed shock in the 
SHOCK trial.   Although LV performance was measured most often on inotropic and intra-
aortic  balloon counterpulsation  support,  both  of  which  increase  EF,  the  hemodynamic 
measurements obtained concurrently document persistent hypotension, low CO, and high filling 
pressures.
Patients with remote MI or dilated cardiomyopathy and mild to moderate chronic CHF 
often have EFs considerably lower than this and are not in shock. These observations highlight 
the  role  of  ventricular  dilation to  maintain  stroke  volume  and  peripheral  vascular  and 
neurohormonal adaptation in chronic CHF. However, an EF in the low 30s is not uncommon in 
uncomplicated patients with recent MI who do not have CHF. 
The classic notion that acute reduction in CO leads to compensatory vasoconstriction 
was not confirmed in many patients in the SHOCK registry and trial (Menon et al(30) and 
Hochman et al, ). SVR varied widely but on average was not elevated at 1350 to 1400 dyne · s 
· cm-5 despite vasopressors use. 
Cotter et al(31,32) categorized acute heart failure patients according to cardiac power 
and demonstrated its importance in risk stratification and selection of therapy. Cardiac power, 
the  product of  cardiac index and mean arterial  pressure,  is  a  useful  prognostic  indicator in 
chronic heart failure. Acute heart failure patients with very high SVR and reduced CO have 
high cardiac power indices, in contrast to most shock patients, who have low cardiac power. 
In both the SHOCK trial and the SHOCK registry, cardiac power was the hemodynamic 
variable most strongly associated with mortality. A small subset of patients in the SHOCK 
registry  was  clinically diagnosed  with  CS  without  hypotension  based  on  systemic 
hypoperfusion, low CO,  and  elevated  ventricular  filling  pressures.  In  these patients,  blood 
pressure was maintained by elevated SVR. Their in-hospital mortality rate (although high at 
43%) was lower than the rate of those patients with classic hypotensive shock (66%), despite 
the 2 groups having the same LVEF (34%), cardiac index (1.9 L/min per m2), and pulmonary 
capillary wedge pressure (25 mm Hg). 
The ability to vasoconstrict vascular beds that supply nonvital organs is an important 
compensatory  response to  a  reduction  in  CO.  Vasodilators  (endogenous  and  exogenous) 
interferes  with this  critical  response,  which is  needed to  maintain flow to the  cerebral  and 
coronary  circulations.  Cardiac  power is  also  prognostically  important  because  it  reflects 
myocardial reserve adequate to generate flow, albeit reduced, in the face of high resistance. 
A clinically  overt  systemic  inflammatory  response syndrome as evidenced by  fever, 
elevated white blood cell count, and low SVR, was observed in many patients with confirmed 
shock complicating acute MI in the randomized SHOCK trial.  These findings often led to a 
secondary clinical diagnosis of suspected sepsis. However, the low SVR despite vasopressors 
was documented at shock onset, days before sepsis was suspected.(33) 
The classic notion that CS develops when 40% of the LV is irreversibly  damaged is 
inconsistent with the following observations: 
(1) Survival of 50% of patients, who undergo early revascularization, 
(2) Evidence of improved EF in some patients following revascularization, and 
(3) New York Heart Association CHF class I for 58% of patients after shock. 
Resolution  of  severe  ischemia  and/or  neurohormonal-inflammatory abnormalities 
explains the complete reversibility of the shock state in some patients. The wide variation in 
EF, LV size, and SVR in the SHOCK trial suggests that the pathophysiology of shock varies 
among patients. 
 A New Paradigm
A  systemic  inflammatory  response  syndrome  occurs  in  the  setting of  a  number  of 
noninfectious, major systemic insults, including trauma, cardiopulmonary bypass, pancreatitis, 
and burns. Patients with large MIs often have elevation of body temperature, white blood cell 
count,  complement,  interleukins,  C-reactive protein,  and  other  inflammatory  markers.  NO, 
synthesized at low levels by endothelial and myocardial cell endothelial nitric oxide (eNOS), is 
a cardio protective molecule.(33,34)
In contrast, many cell types express iNOS at pathological levels after trauma or exposure 
to  inflammatory  mediators  (ie,  bacterial  lipopolysaccharide, tumor  necrosis  factor- ,  and 
interleukin-1). Such expression may lead to toxic levels of NO and the cytotoxic NO-derived 
species, peroxynitrite, formed by reaction with superoxide. In experimental models, high iNOS 
and NO levels are seen after MI and subsequent reperfusion. Release of cytokines by the heart 
